JNJ 61186372

Drug Profile

JNJ 61186372

Alternative Names: Bispecific EGFR-cMet antibody

Latest Information Update: 07 Jul 2016

Price : $50

At a glance

  • Originator Genmab; Janssen Research & Development
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action Epidermal growth factor receptor antagonists; Immunomodulators; Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-small cell lung cancer

Most Recent Events

  • 01 May 2016 Janssen Research & Development initiates a phase I trial for Non-small cell lung cancer (Metastatic disease, Inoperable/Unresectable) in South Korea (IV) (NCT02609776)
  • 31 Dec 2015 Phase-I clinical trials in Non-small cell lung cancer (Metastatic disease, Inoperable/Unresectable) in South Korea (IV)
  • 24 Nov 2015 Preclinical trials in Non-small cell lung cancer in USA (Parenteral) before November 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top